Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Imgn-853
2. Imgn853
1. Humov 19
2. Unii-98de7vn88d
3. Imgn853
4. Imgn 853
5. Mirvetuximab Soravtansine [usan]
6. Mirvetuximab-soravtansine
7. 98de7vn88d
8. Imgn-853
9. Schembl16447449
10. 1453084-37-1
11. Immunoglobulin G1, Anti-(human Folate Receptor Alpha) (human-mus Musculus Monoclonal M9346a Heavy Chain), Disulfide With Human-mus Musculus Monoclonal M9346a Light Chain, Dimer, Tetraamide With N2'-(4-((3-carboxy-3-sulfopropyl)dithio)-4-methyl-1-oxopentyl)-n2'-deacetylmaytansine
12. Q27272114
| Molecular Weight | 977.6 g/mol |
|---|---|
| Molecular Formula | C42H61ClN4O14S3 |
| XLogP3 | 1.8 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 16 |
| Rotatable Bond Count | 16 |
| Exact Mass | 976.3034938 g/mol |
| Monoisotopic Mass | 976.3034938 g/mol |
| Topological Polar Surface Area | 313 Ų |
| Heavy Atom Count | 64 |
| Formal Charge | 0 |
| Complexity | 1890 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 8 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 2 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Treatment of fallopian tube cancer , Treatment of ovarian carcinoma, Treatment of peritoneal carcinoma
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
STOCK RECAP #PipelineProspector
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Mirvetuximab Soravtansine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Mirvetuximab Soravtansine, including repackagers and relabelers. The FDA regulates Mirvetuximab Soravtansine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Mirvetuximab Soravtansine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Mirvetuximab Soravtansine supplier is an individual or a company that provides Mirvetuximab Soravtansine active pharmaceutical ingredient (API) or Mirvetuximab Soravtansine finished formulations upon request. The Mirvetuximab Soravtansine suppliers may include Mirvetuximab Soravtansine API manufacturers, exporters, distributors and traders.
Mirvetuximab Soravtansine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Mirvetuximab Soravtansine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Mirvetuximab Soravtansine GMP manufacturer or Mirvetuximab Soravtansine GMP API supplier for your needs.
A Mirvetuximab Soravtansine CoA (Certificate of Analysis) is a formal document that attests to Mirvetuximab Soravtansine's compliance with Mirvetuximab Soravtansine specifications and serves as a tool for batch-level quality control.
Mirvetuximab Soravtansine CoA mostly includes findings from lab analyses of a specific batch. For each Mirvetuximab Soravtansine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Mirvetuximab Soravtansine may be tested according to a variety of international standards, such as European Pharmacopoeia (Mirvetuximab Soravtansine EP), Mirvetuximab Soravtansine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Mirvetuximab Soravtansine USP).
LOOKING FOR A SUPPLIER?
